JNJ

239.99

+0.58%↑

UNH

273.88

-1.05%↓

TMO

541.25

-1.25%↓

ABT

112.24

+1.31%↑

ISRG

497.33

+0.87%↑

JNJ

239.99

+0.58%↑

UNH

273.88

-1.05%↓

TMO

541.25

-1.25%↓

ABT

112.24

+1.31%↑

ISRG

497.33

+0.87%↑

JNJ

239.99

+0.58%↑

UNH

273.88

-1.05%↓

TMO

541.25

-1.25%↓

ABT

112.24

+1.31%↑

ISRG

497.33

+0.87%↑

JNJ

239.99

+0.58%↑

UNH

273.88

-1.05%↓

TMO

541.25

-1.25%↓

ABT

112.24

+1.31%↑

ISRG

497.33

+0.87%↑

JNJ

239.99

+0.58%↑

UNH

273.88

-1.05%↓

TMO

541.25

-1.25%↓

ABT

112.24

+1.31%↑

ISRG

497.33

+0.87%↑

Strona główna・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Open

SectorHealthcare

38.01 4.14

Buy Sell

Overview

Share price change

24h

Current

Min

36.41

Max

38.18

Key metrics
By Trading Economics
Income	11M 51M
Sales	39M 239M
P/E Sector Avg	11.937 84.243
EPS	1.08
Profit margin	21.242
Employees	268
EBITDA	14M 73M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+28.56% upside

Dividends
By Dow Jones
Next Earnings	24 lut 2026

Market Stats
By TradingEconomics
Market Cap	492M 2.2B
Previous open	33.87
Previous close	38.01

News Sentiment

By Acuity

34%

66%

80 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

29.8 / N/A Support & Resistance

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 lut 2026, 17:25 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9 lut 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9 lut 2026, 23:43 UTC

Market Talk

Gold Falls on Possible Technical Correction -- Market Talk

9 lut 2026, 23:14 UTC

Market Talk

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9 lut 2026, 22:29 UTC

Market Talk

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9 lut 2026, 22:19 UTC

Market Talk

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9 lut 2026, 22:08 UTC

Market Talk

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9 lut 2026, 22:01 UTC

Earnings

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9 lut 2026, 21:59 UTC

Earnings

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9 lut 2026, 21:59 UTC

Earnings

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9 lut 2026, 21:58 UTC

Earnings

Friedman Industries 3Q Sales $168M >FRD

9 lut 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

9 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 lut 2026, 21:48 UTC

Earnings

Friedman Industries 3Q EPS 43c >FRD

9 lut 2026, 21:17 UTC

Earnings

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9 lut 2026, 21:13 UTC

Market Talk

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9 lut 2026, 21:04 UTC

Earnings

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9 lut 2026, 20:30 UTC

Market Talk

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9 lut 2026, 20:02 UTC

Market Talk

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9 lut 2026, 19:42 UTC

Market Talk

Japan's Yield Curve Expected to Flatten -- Market Talk

9 lut 2026, 19:31 UTC

Market Talk

Nike Seen Regaining Relevance With Consumers -- Market Talk

9 lut 2026, 19:27 UTC

Market Talk

Gold Climbs Back Over $5,000/oz -- Market Talk

9 lut 2026, 19:05 UTC

Market Talk

Nike Returns to List of Hottest Brands -- Market Talk

9 lut 2026, 18:19 UTC

Market Talk

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9 lut 2026, 17:41 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9 lut 2026, 17:31 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9 lut 2026, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

9 lut 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 lut 2026, 17:17 UTC

Market Talk

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9 lut 2026, 17:16 UTC

Earnings

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

28.56% upside

12 Months Forecast

Average 47.67 USD 28.56%

High 55 USD

Low 42 USD

Based on 4 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

80 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.